Holen Sie sich die Stockscreener-App
2.32
0.87%
0.02
Schlusskurs vom Vortag:
$2.30
Offen:
$2.34
24-Stunden-Volumen:
656.92K
Relative Volume:
0.31
Marktkapitalisierung:
$277.98M
Einnahmen:
$6.65M
Nettoeinkommen (Verlust:
$-136.32M
KGV:
-2.0214
EPS:
-1.1477
Netto-Cashflow:
$-112.04M
1W Leistung:
-1.28%
1M Leistung:
-5.31%
6M Leistung:
+90.16%
1J Leistung:
+91.74%
1-Tages-Spanne:
$2.27
$2.36
1-Wochen-Bereich:
$2.27
$2.495
52-Wochen-Spanne:
$0.95
$3.23
Fate Therapeutics Inc Stock (FATE) Company Profile
Firmenname
Fate Therapeutics Inc
Sektor
Branche
Telefon
858.875.1803
Adresse
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
2.32 | 281.58M | 6.65M | -136.32M | -112.04M | -1.1477 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-05-19 | Fortgesetzt | Jefferies | Buy |
| 2025-10-31 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-11-18 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-06-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-01-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | Herabstufung | Stifel | Buy → Hold |
| 2023-01-06 | Herabstufung | Truist | Buy → Hold |
| 2023-01-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-12-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-12-15 | Eingeleitet | Goldman | Sell |
| 2022-11-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-10-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-07-28 | Eingeleitet | Needham | Hold |
| 2022-07-11 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Market Perform |
| 2021-12-15 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-11-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-06-07 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Jefferies | Buy |
| 2021-02-26 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-02-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-27 | Fortgesetzt | H.C. Wainwright | Neutral |
| 2020-05-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-09 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | Bestätigt | Mizuho | Buy |
| 2019-12-09 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-06-07 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-31 | Eingeleitet | Guggenheim | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2019-03-28 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-03 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | Eingeleitet | Jefferies | Buy |
| 2018-08-01 | Eingeleitet | Citigroup | Buy |
| 2018-03-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Alle ansehen
Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten
Fate Therapeutics, Inc. (FATE) stock price, news, quote and history - uk.finance.yahoo.com
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences - GlobeNewswire
FRAUD AND MANIPULATION—S.D. Cal.: Pharma company ducks securities fraud claim for lack of loss causation - VitalLaw.com
Gross profit of Fate Therapeutics, Inc. – HAN:F6T - TradingView
Is Fate Therapeutics (NASDAQ:FATE) Rewriting the Healthcare Stocks Playbook? - kalkinemedia.com
Fate Therapeutics, Inc. (FATE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fate Therapeutics Receives $15 Million Grant for Lupus Treatment Trial - Yahoo Finance
Fate Therapeutics receives $15m CIRM grant for lupus trial By Investing.com - Investing.com Nigeria
Fate Therapeutics receives $15m CIRM grant for lupus trial - Investing.com India
Fate Therapeutics Receives $15 Million CIRM Grant to Advance Phase 2 RECLAIM-LN Trial of FT819 in Lupus Nephritis - Quiver Quantitative
Fate Therapeutics Announces Receipt of California Institute - GlobeNewswire
Fate Therapeutics Inc (F6T.MU) stock price, news, quote and history - uk.finance.yahoo.com
Longeveron slides 59% after-hours from stem cell therapy study failure - Mugglehead Investment Magazine
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 - The Manila Times
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by Analysts - MarketBeat
Fate Therapeutics presents FT819 lupus trial data at conference By Investing.com - Investing.com Nigeria
Fate Therapeutics at Cantor conference: autoimmune CAR-T push advances By Investing.com - Investing.com Canada
FATE: Scalable CAR T platform shows strong safety, efficacy, and promising phase II progress in lupus nephritis - TradingView
Fate Therapeutics to Present FT819 and FT839 Data at CCR West Meeting, Highlighting Safety and Efficacy in Autoimmune Disease - Quiver Quantitative
FATE News | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill
Fate Therapeutics Announces Encore Clinical Data - GlobeNewswire
Fate Therapeutics Market Sentiment - Benzinga España
FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials - Stocktwits
Fate Therapeutics (FATE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
Fate Therapeutics stock holds steady as investors watch cash runway and pipeline - ad-hoc-news.de
FATE Q2 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline Drives FocusPost-Earnings Drift - vinanet.vn
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference - Yahoo Finance
BlackRock Inc. Makes New Investment in Fate Therapeutics, Inc. $FATE - MarketBeat
Fate Therapeutics stock stabilizes after autoimmune CAR-T safety shock - ad-hoc-news.de
Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead (NASDAQ:FATE) - Seeking Alpha
574,995 Shares in Fate Therapeutics, Inc. $FATE Acquired by Connor Clark & Lunn Investment Management Ltd. - MarketBeat
487,728 Shares in Fate Therapeutics, Inc. $FATE Acquired by Ieq Capital LLC - marketbeat.com
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Fate Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
symbol__ Stock Quote Price and Forecast - CNN
Fate Therapeutics (FATE) Gains 1.98% to $2.57 as Stock Holds Above Key SupportStock News - dars.gov.et
Johnson & Johnson Makes New $9.12 Billion Investment in Fate Therapeutics, Inc. $FATE - MarketBeat
Fate Therapeutics (FATE) Rises 1.98% to $2.57 as it Approaches Key ResistanceAdvance Decline Line - vinanet.vn
Dimensional Fund Advisors LP Lowers Stock Holdings in Fate Therapeutics, Inc. $FATE - MarketBeat
Fate Therapeutics earnings beat by $0.02, revenue topped estimates - Investing.com Australia
Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Raises Target Price to $8 - Moomoo
Fate Therapeutics Initiates Potentially Registrational Trial of Off-the-Shelf CAR T-Cell Therapy FT819 for Lupus Nephritis - BioPharm International
Fate Therapeutics Is Maintained at Equal-Weight by Wells Fargo - Moomoo
Wedbush Reaffirms "Outperform" Rating for Fate Therapeutics (NASDAQ:FATE) - MarketBeat
Fate Therapeutics doses first patient in FT819 lupus trial - Investing.com
Fate Therapeutics doses first patient in FT819 lupus trial By Investing.com - Investing.com Nigeria
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis - TradingView
Fate Therapeutics Doses First Patient in Phase 2 RECLAIM-LN Trial of FT819 for Lupus Nephritis - Quiver Quantitative
Fate Therapeutics' First FT819 Patient Went Home Same Day - Stock Titan
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis - The Manila Times
FATE THERAPEUTICS, INC. : WELLS FARGO RAISES TARGET PRICE TO $3.5 FROM $2.5 - Bitget
Finanzdaten der Fate Therapeutics Inc-Aktie (FATE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Fate Therapeutics Inc-Aktie (FATE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Valamehr Bahram | President and CEO |
Aug 04 '26 |
Sale |
2.46 |
43,947 |
108,101 |
591,815 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):